Azenta Announces the Election of Dipal Doshi to its Board of Directors
Azenta (NASDAQ: AZTA) announced the election of Dipal Doshi to its Board of Directors at its Annual Meeting of Stockholders. Doshi, who currently serves as the Chief Executive Officer of Entrada Therapeutics (NASDAQ: TRDA), brings extensive experience in the biotechnology and pharmaceutical industries.
John Marotta, President and CEO of Azenta, highlighted Doshi's exceptional leadership qualities and valuable experience in strategy, operational and commercial growth, along with his perspective as a current public company CEO. Doshi expressed enthusiasm about joining Azenta during a important period in its development, emphasizing the company's strong market leadership position and commitment to growth and innovation.
Azenta (NASDAQ: AZTA) ha annunciato l'elezione di Dipal Doshi nel suo Consiglio di Amministrazione durante l'Assemblea Annuale degli Azionisti. Doshi, attualmente Amministratore Delegato di Entrada Therapeutics (NASDAQ: TRDA), porta con sé una vasta esperienza nei settori della biotecnologia e della farmaceutica.
John Marotta, Presidente e CEO di Azenta, ha messo in evidenza le eccezionali qualità di leadership e l'esperienza preziosa di Doshi in termini di strategia, crescita operativa e commerciale, insieme alla sua prospettiva come attuale CEO di una società pubblica. Doshi ha espresso entusiasmo per l'accettazione dell'incarico in Azenta in un periodo cruciale per lo sviluppo dell'azienda, sottolineando la forte posizione di leadership sul mercato e l'impegno verso la crescita e l'innovazione.
Azenta (NASDAQ: AZTA) anunció la elección de Dipal Doshi para su Junta Directiva en su Reunión Anual de Accionistas. Doshi, quien actualmente se desempeña como Director Ejecutivo de Entrada Therapeutics (NASDAQ: TRDA), aporta una amplia experiencia en las industrias de biotecnología y farmacéutica.
John Marotta, Presidente y CEO de Azenta, destacó las excepcionales cualidades de liderazgo de Doshi y su valiosa experiencia en estrategia, crecimiento operativo y comercial, así como su perspectiva como CEO de una empresa pública. Doshi expresó su entusiasmo por unirse a Azenta en un período importante de su desarrollo, enfatizando la fuerte posición de liderazgo en el mercado y el compromiso con el crecimiento y la innovación.
Azenta (NASDAQ: AZTA)는 주주 총회에서 Dipal Doshi를 이사회에 선임했다고 발표했습니다. Doshi는 현재 Entrada Therapeutics (NASDAQ: TRDA)의 CEO로 재직 중이며, 생명공학 및 제약 산업에서 폭넓은 경험을 가지고 있습니다.
Azenta의 회장이자 CEO인 John Marotta는 Doshi의 뛰어난 리더십과 전략, 운영 및 상업 발전에 대한 귀중한 경험, 현재의 상장 회사 CEO로서의 관점을 강조했습니다. Doshi는 Azenta에 합류하게 되어 기쁘다고 전하며, 회사의 강력한 시장 리더십과 성장 및 혁신에 대한 헌신을 강조했습니다.
Azenta (NASDAQ: AZTA) a annoncé l'élection de Dipal Doshi au sein de son Conseil d'Administration lors de son Assemblée Générale Annuelle des Actionnaires. Doshi, qui occupe actuellement le poste de Directeur Général d'Entrada Therapeutics (NASDAQ: TRDA), apporte une vaste expérience dans les secteurs de la biotechnologie et de la pharmacie.
John Marotta, Président et CEO d'Azenta, a souligné les qualités de leadership exceptionnelles de Doshi et son expérience précieuse en matière de stratégie, de croissance opérationnelle et commerciale, ainsi que sa perspective en tant qu'actuel CEO d'une entreprise cotée en bourse. Doshi a exprimé son enthousiasme à rejoindre Azenta durant une période importante pour son développement, en mettant l'accent sur la position de leadership forte de l'entreprise sur le marché et son engagement envers la croissance et l'innovation.
Azenta (NASDAQ: AZTA) gab die Wahl von Dipal Doshi in seinen Vorstand auf der jährlichen Aktionärsversammlung bekannt. Doshi, der derzeit als CEO von Entrada Therapeutics (NASDAQ: TRDA) tätig ist, bringt umfangreiche Erfahrungen aus der Biotechnologie- und Pharmaindustrie mit.
John Marotta, Präsident und CEO von Azenta, hob Doshi's außergewöhnliche Führungsqualitäten und wertvolle Erfahrungen in Strategie, operativem und kommerziellem Wachstum hervor, ebenso wie seine Perspektive als aktueller CEO eines börsennotierten Unternehmens. Doshi äußerte seine Begeisterung, Azenta in einer wichtigen Phase seiner Entwicklung beizutreten, und betonte die starke Marktführerschaft und das Engagement für Wachstum und Innovation des Unternehmens.
- Addition of experienced biotech CEO to the board strengthens corporate governance
- Strategic expertise gained from leader with biotechnology and pharmaceutical industry background
- None.
"Mr. Doshi is an extraordinary leader who brings significant experience in the biotechnology and pharmaceutical industries," said John Marotta, President and CEO of Azenta. "His experience in strategy, operational and commercial growth, and perspective as a current public company CEO make him a perfect fit for our Board.
"I am excited to be joining Azenta at a critical time in their evolution," said Dipal Doshi. "Azenta's strong market leadership position and its commitment to growth and innovation is clear. I look forward to collaborating with the Board and the leadership team to help shape the company's future and make a meaningful impact."
About Dipal Doshi
Mr. Doshi is the CEO of Entrada Therapeutics and a Member of its Board of Directors. He previously served as President and CEO from 2017 to 2023. Mr. Doshi has led critical functions in biotechnology and pharmaceutical companies, including roles focused on business development, corporate strategy, new product planning, commercial planning and finance. Prior to joining Entrada, Mr. Doshi was the Chief Business Officer at Amicus Therapeutics, a global biotechnology company focused on rare diseases. He has also held senior-level positions at a healthcare private equity fund and Catalent. Earlier in his career, Mr. Doshi worked in Merrill Lynch's Investment Banking Group and held several roles at Eli Lilly and Company.
Mr. Doshi holds an MBA from The Wharton School of the University of
About Azenta Life Sciences
Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.
Azenta is headquartered in Burlington, MA, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com.
INVESTOR CONTACTS:
Yvonne Perron
Vice President, Financial Planning & Analysis, and Investor Relations
ir@azenta.com
Sherry Dinsmore
sherry.dinsmore@azenta.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/azenta-announces-the-election-of-dipal-doshi-to-its-board-of-directors-302364799.html
SOURCE Azenta
FAQ
Who is the newest board member elected to Azenta (AZTA) in January 2024?
What experience does Dipal Doshi bring to Azenta's (AZTA) board?
When was Dipal Doshi nominated to Azenta's (AZTA) board?
How many directors were re-elected alongside Dipal Doshi to Azenta's (AZTA) board?
